Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy

ConclusionAdministration of adjuvant eribulin after neoadjuvant chemotherapy was feasible and well tolerated. The 24-month DFS rate did not reach the study target levels in any of the cohorts and was similar to DFS previously described in these cohorts following neoadjuvant chemotherapy alone.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research

Related Links:

Development of recurrence risk score using 95‑gene classifier and its application to formalin‑fixed paraffin‑embedded tissues in ER‑positive, HER2‑negative and node‑negative breast cancer. Oncol Rep. 2019 Oct 07;: Authors: Naoi Y, Saito Y, Kishi K, Shimoda M, Kagara N, Miyake T, Tanei T, Shimazu K, Kim SJ, Noguchi S Abstract We previously developed a 95‑gene classifier (95GC) to classify ER‑positive/HER2‑negative/node‑negative (ER+/HER2‑/N0) breast cancer as high‑ and low‑risk. The present study aimed to devise a 95GC recurrence score (95GCRS) to estimate recurrence risk ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Mangone L, Mancuso P, Tagliabue G, Filiberti RA, Carrozzi G, Iacovacci S, Mazzucco W, Tumino R, Minicozzi P, Sant M, Giorgi Rossi P Abstract OBJECTIVE: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I-III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. METHODS: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009-2013). Included were 3546 women aged
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Publication date: Available online 22 June 2019Source: Journal of Geriatric OncologyAuthor(s): Etienne Brain, Philippe Caillet, Nienke de Glas, Laura Biganzoli, Karis Cheng, Lissandra Dal Lago, Hans WildiersAbstractHER2-positive (HER2+) breast cancer (BC) affects older women nearly as frequently as younger ones. Many older patients have cardiovascular comorbidity and risk greater toxicity from therapy. Treatment therefore requires careful consideration, especially since trials include few patients over 65 and so provide limited guidance. A multidisciplinary task force of the International Society of Geriatric Oncology cond...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Abstract BACKGROUND: High-volume single-institution studies support the oncologic safety of nipple sparing mastectomy (NSM). Concerns remain regarding the increased potential for complications, recurrence, and delays to subsequent adjuvant therapy. A national database was used to examine treatment and outcomes for NSM patients. METHODS: Women undergoing unilateral NSM or skin sparing mastectomy (SSM) for stage 0-4 breast cancer from 2004 to 2013 were identified from the National Cancer Database. Demographic and oncologic characteristics, short-term outcomes and time to local and systemic treatment were compar...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
CONCLUSIONS: This study confirmed the therapeutic impact of lapatinib, trastuzumab, and paclitaxel therapy for each ER- and ER+ subgroup of HER2+ patients. Development of further strategies and tools is required, particularly for luminal HER2 disease. PMID: 29445928 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
ConclusionsOn-treatment TILs, but not baseline TILs, are independently associated with response following anti-HER2 therapy-only. A combined score of TILs and tumor cellularity measured at D15 provides independent predictive information upon completion of neoadjuvant anti-HER2-based therapy.Clinical trial numberNCT01973660.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, this combined metabolic approach appears effective in treating advanced TNBC, given this patient’s complete response with a good quality of life.Now, there is one thing that is interesting here. The doses of chemotherapy used were considerably lower thanwhat is usually used, with doses decreased by at least half or more. Does this mean anything? Who knows? cPR rates for TNBC have been reported to range from 20-35%. It could mean the regimen made the chemotherapy more effective, or it could mean that this woman just happened to have a particularly chemosensitive tumor. Even if we take this case report a...
Source: Respectful Insolence - Category: Surgery Authors: Source Type: blogs
In conclusion, this combined metabolic approach appears effective in treating advanced TNBC, given this patient’s complete response with a good quality of life.Now, there is one thing that is interesting here. The doses of chemotherapy used were considerably lower thanwhat is usually used, with doses decreased by at least half or more. Does this mean anything? Who knows? cPR rates for TNBC have been reported to range from 20-35%. It could mean the regimen made the chemotherapy more effective, or it could mean that this woman just happened to have a particularly chemosensitive tumor. Even if we take this case report a...
Source: Respectful Insolence - Category: Surgery Authors: Source Type: blogs
AbstractBackgroundAlthough 1% has been used as cut-off for estrogen receptor (ER) positivity, several studies have reported that tumors with ER  
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: In this study we developed a decision treatment model for patients with DCIS based on Bayesian Decision Theory. The results were consistent with scientific evidence and clinical practice. Finally, we performed the computer implementation of the model in order to be used in routine clinical practice.DISCUSION: The model developed in the study is the first decision model that takes into account the uncertainty calculation based on the expected utility of each decision on recurrence-free survival for each patient.Citation Format: Fujiki Y, Yamamoto Y, Yamamoto-Ibusuki M, Goto R, Tomiguchi M, Sueta A, Takeshita T,...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Herceptin | Hormonal Therapy | Hormones | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Study